On July 9th, Prelude Therapeutics, a precision oncology company in the clinical stage, announced the signing of a clinical trial cooperation and supply agreement with MSD. According to the terms of the agreement, Phase 2 clinical studies will evaluate the efficacy of PRT3789 in combination with Merck's anti-PD-1 tumor immunotherapy KEYTRUDA in the treatment of SMARCA4 mutant cancer patients.